30 November 2020: Clinical Research
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
Chang Liu 12CDEF* , Ting Li 12CDEF* , Zhonghua Tao 12B , Jun Cao 12B , Leiping Wang 12B , Jian Zhang 12B , Biyun Wang 12A* , Xichun Hu 12A*DOI: 10.12659/MSM.927187
Med Sci Monit 2020; 26:e927187
Table 2 Treatment pattern of palbociclib-based treatment in different treatment-line settings.
| Characteristic | All patients (n=130) | 1st line (n=42) | ≥2nd line (n=88) | ≥4th line (n=19) |
|---|---|---|---|---|
| SERM | 12 (9.2%) | 0 (0.0%) | 12 (13.6%) | 7 (36.8%) |
| Tamoxifen | 2 (1.5%) | 0 (0.0%) | 2 (2.3%) | 2 (10.5%) |
| Toremifene | 10 (7.7%) | 0 (0.0%) | 10 (11.4%) | 5 (26.3%) |
| AI | 62 (47.7%) | 21 (50.0%) | 41 (46.6%) | 9 (47.4%) |
| Anatrozole | 13 (10.0%) | 5 (11.9%) | 8 (9.1%) | 2 (10.5%) |
| Letrozole | 30 (23.1%) | 12 (28.6%) | 18 (20.5%) | 6 (31.6%) |
| Exemestane | 19 (14.6%) | 4 (9.5%) | 15 (17.0%) | 1 (5.3%) |
| SERD | 56 (43.1%) | 21 (50.0%) | 35 (39.8%) | 3 (15.8%) |
| Yes | 19 (14.6%) | 1 (2.4%) | 18 (20.5%) | 6 (31.6%) |
| No | 111 (85.4%) | 41 (97.6%) | 70 (79.5%) | 13 (68.4%) |
| Start at 125 mg/day | 113 (87.0%) | 33 (78.6%) | 80 (90.9%) | 16 (84.2%) |
| Reduction to 100 mg/day | 11 (8.5%) | 6 (14.3%) | 5 (5.7%) | 2 (10.5%) |
| Start at 100 mg/day | 15 (11.5%) | 7 (16.7%) | 8 (9.1%) | 3 (15.8%) |
| Start at 75 mg/day | 2 (1.5%) | 2 (4.8%) | 0 (0.0%) | 0 (0.0%) |
| ET – endocrine therapy; SERM – selective estrogen receptor modulator; AI – aromatase inhibitor; SERD – selective estrogen receptor degrader. | ||||